Annual Meeting to be adjourned solely with respect to Item 2, and Item 2 to be modified to decrease the proposed aggregate number of shares of common stock that the Company would be authorized to issue from 500,000,000 shares to 400,000,000 shares Annual Meeting to be adjourned solely with respect to Item 2, and Item 2 to be modified to decrease the proposed aggregate number of shares of common stock that the Company would be authorized to issue from 500,000,000 shares to 400,000,000 shares

Read more here:
Ocugen Inc. Announces Plan to Adjourn Annual Meeting of Stockholders, Modify Proposal Regarding Increase in Number of Authorized Shares

COPENHAGEN, Denmark, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Evaxion Biotech, a clinical-stage biotechnology company developing AI-driven immunotherapies, announces today the dosing of the first patient in a Phase I/IIa clinical trial of its adjuvant immunotherapy EVX-02, in combination with checkpoint inhibitors in patients with advanced melanoma.

See the rest here:
Evaxion Biotech Doses First Patient in Phase I/IIa Melanoma Trial of Cancer Vaccine EVX-02 in Combination With Checkpoint Inhibitors

Novadip Biosciences Receives Rare Paediatric Disease Priority Review and Orphan Disease Designation

Visit link:
Novadip Biosciences Receives Rare Paediatric Disease Priority Review and Orphan Disease Designation

VANCOUVER, Dec. 22, 2020 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) CSE: BETR / OTCQB: BETRF / FRA: NPAU) an emerging biotech company, is pleased to announce that Patrick Kroupa and Justin Kirkland, two industry leaders in psychedelic therapeutics, have joined the Company. Mr. Kroupa and Mr. Kirkland will join the senior management team of BetterLife as Chief Psychedelics Officer and Chief Psychedelics Scientist, respectively.

Go here to read the rest:
BetterLife Welcomes Psychedelic Industry Leaders to the Senior Management Team

NEW YORK, NY, REHOVAT, ISRAEL, SINGAPORE, Dec. 23, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for early detection of cancer and Alzheimer’s disease, today announced that it has entered into a preferred vendor agreement to supply COVID-19 related testing products and services to Natural Wellness Clinics (“NWC”) for use in its efforts in testing the uninsured population in the Commonwealth of Kentucky. NWC is a US military veteran owned health care provider that offers communities a holistic and integrative approach and is establishing a niche in implementing large-scale testing programs and logistics for state governments that it hopes may dovetail into vaccine distribution logistics.

Continued here:
Todos Medical Announces Agreement to Supply Natural Wellness Clinics with COVID-19 Testing Products to Support Initiatives in the Commonwealth of...

The Company began enrolling patients in Saturn-1 in September 2020 and expects to initiate its second pivotal registration trial, Saturn-2, in 2021 The Company began enrolling patients in Saturn-1 in September 2020 and expects to initiate its second pivotal registration trial, Saturn-2, in 2021

Read the rest here:
Tarsus Pharmaceuticals, Inc. Announces Type C Meeting with FDA Regarding NDA Submission Requirements for Lead Candidate TP-03

Read the original:
Avicanna to Expand Access to Its Advanced and Evidence-Based RHO Phyto Medical Products Through Provincial Retailers Across Canada

NEW YORK and MAINZ, GERMANY, December 23, 2020 (GLOBE NEWSWIRE) — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a second agreement with the U.S. government to supply an additional 100 million doses of the companies’ COVID-19 vaccine from production facilities in the U.S. This agreement brings the total number of doses to be delivered to the U.S. to 200 million. The companies expect to deliver the full 200 million doses to Operation Warp Speed (OWS) by July 31, 2021. Consistent with the original agreement announced in July 2020, the U.S. government will pay $1.95 billion for the additional 100 million doses.

Read the original post:
Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine

--Dr. Dunne resigns as Chief Scientific Officer---- Steven Aronin, M.D., Senior Vice President and Head of Clinical Development, to lead Development and Regulatory Activities--

Go here to read the rest:
Iterum Therapeutics Announces Transition of Michael Dunne, M.D. to Strategic Advisor and Member of the Board of Directors

SAN FRANCISCO, Dec. 23, 2020 (GLOBE NEWSWIRE) -- UC San Francisco (UCSF) and BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a partnership to drive the advancement of academic innovations in genetically driven diseases into potential therapeutics for patients.

See the original post here:
UCSF and BridgeBio Pharma Collaborate to Accelerate the Development of Therapies for Genetic Diseases

TORONTO, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Auxly Cannabis Group Inc. (TSX.V - XLY) ("Auxly" or the “Company”), a consumer packaged goods company in the cannabis products market, is thrilled to announce that its wholly owned subsidiary, KGK Science Inc. (“KGK”) has received its Institutional Cannabis Research Licence from Health Canada pursuant to the Cannabis Act. In addition to the two project-specific cannabis research licences, and the licence to conduct sensory trials currently held by KGK, this Institutional licence provides the contract research organization with approval to conduct multiple cannabis research projects, removing the need to obtain individual research licences for each project, thereby increasing its flexibility and expediting processes at its clinical research facility located in London, Ontario.

See original here:
Auxly’s Subsidiary KGK Science Receives Institutional Cannabis Research Licence from Health Canada

Read the original:
Recce Announces Positive Intranasal Animal Data against SARS-CoV-2 in International Study

NEW YORK and MAINZ, GERMANY, December 23, 2020 (GLOBE NEWSWIRE) — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a second agreement with the U.S. government to supply an additional 100 million doses of the companies’ COVID-19 vaccine from production facilities in the U.S. This agreement brings the total number of doses to be delivered to the U.S. to 200 million. The companies expect to deliver the full 200 million doses to Operation Warp Speed (OWS) by July 31, 2021. Consistent with the original agreement announced in July 2020, the U.S. government will pay $1.95 billion for the additional 100 million doses.

See the original post here:
Correction: Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine

Continued here:
AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 ‘Long Haulers’

The new agreement will provide Lonza with access to Arbor’s gene editing technology

Read more:
Arbor Biotechnologies and Lonza Enter into Gene Editing Technology Licensing Deal

Follow this link:
Bespoke Extracts Welcomes Mixed Martial Artists Paige VanZant and Austin Vanderford to the Growing Team of Bespoke CBD Brand Ambassadors

TORONTO, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today announced it has arranged a non-brokered private placement offering of 430,000 common shares priced at $1.50 per common share (the “Common Shares”) for gross proceeds of $500,000 USD (approximately $645,000 CAD) (the “Offering”).

Continue reading here:
Arch Biopartners Arranges Non-Brokered Private Placement

TORONTO, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19. The Company is on pace to meet its enrollment goals for the Independent Data and Safety Monitoring Board (“DSMB”) to review the safety and efficacy data from the 210 patients as part of the first interim analysis of patients treated and followed up for 28 days after randomization.

Link:
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Plans on Emergency Use Access

Hamilton, MT Facility Is Planned to Manufacture Vaccines at Commercial Scale, Including Vaccines Under Development for COVID-19

Visit link:
Tonix Pharmaceuticals Plans Commercial Scale Vaccine Manufacturing Facility

MONMOUTH JUNCTION, N.J., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a?late clinical-stage?biopharmaceutical company?working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg?for use in retinal?indications, today announced its corporate highlights and financial results for its fiscal year ended September 30, 2020.

See the rest here:
Outlook Therapeutics Reports Financial Results for Fiscal Year 2020 and Provides Corporate Update